Merrimack Pharmaceuticals News Releases http://investors.merrimack.com/ Merrimack Pharmaceuticals News Releases en Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend http://investors.merrimack.com/news-releases/news-release-details/merrimack-pharmaceuticals-announces-completion-strategic-review CAMBRIDGE, Mass. , May 30, 2019 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway Thu, 30 May 2019 16:05:00 -0400 Merrimack Pharmaceuticals News Releases 12006 Merrimack Reports First Quarter 2019 Financial Results http://investors.merrimack.com/news-releases/news-release-details/merrimack-reports-first-quarter-2019-financial-results CAMBRIDGE, Mass. , May 10, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial results for the period ended March 31, 2019 . "We continue to focus our efforts on completing Fri, 10 May 2019 07:30:00 -0400 Merrimack Pharmaceuticals News Releases 11981 Merrimack Discontinues Development of MM-310 http://investors.merrimack.com/news-releases/news-release-details/merrimack-discontinues-development-mm-310 -- Safety update shows Phase 1 study unable to reach optimal therapeutic index for MM-310 due to continued observation of cumulative peripheral neuropathy -- -- Company expects to reduce workforce reflective of narrowed preclinical development pipeline; continues to prudently advance programs while Thu, 04 Apr 2019 16:15:00 -0400 Merrimack Pharmaceuticals News Releases 11941 Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results http://investors.merrimack.com/news-releases/news-release-details/merrimack-reports-fourth-quarter-and-full-year-2018-financial CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018 . Wed, 06 Mar 2019 07:00:00 -0500 Merrimack Pharmaceuticals News Releases 11896 Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review http://investors.merrimack.com/news-releases/news-release-details/merrimack-reports-third-quarter-2018-financial-results-and - Company to initiate corporate restructuring, including ~60% reduction in force and significant reduction in operating expenses; potential to extend runway into at least 2H 2022 to preserve ability to capture Ipsen milestones - - Has engaged external advisors to evaluate strategic alternatives - - Wed, 07 Nov 2018 06:45:00 -0500 Merrimack Pharmaceuticals News Releases 11831 Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call http://investors.merrimack.com/news-releases/news-release-details/merrimack-announces-timing-third-quarter-2018-investor CAMBRIDGE, Mass. , Oct. 31, 2018 /PRNewswire/ --   Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2018 investor conference call and webcast at 8:30 am ET on Wednesday, November 7, 2018.   The call will provide an update on Merrimack's Wed, 31 Oct 2018 16:05:00 -0400 Merrimack Pharmaceuticals News Releases 11821 Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility http://investors.merrimack.com/news-releases/news-release-details/merrimack-discontinues-phase-2-sherloc-study-mm-121-patients-non - MM-121 did not improve progression free survival (PFS) in patients with non-small cell lung cancer (NSCLC) - - Company to provide pipeline review update on third quarter financial results call, November 7, 2018 - CAMBRIDGE, Mass. , Oct. 19, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  Fri, 19 Oct 2018 06:00:00 -0400 Merrimack Pharmaceuticals News Releases 11816 Merrimack Receives $5 Million Milestone Payment from Shire http://investors.merrimack.com/news-releases/news-release-details/merrimack-receives-5-million-milestone-payment-shire CAMBRIDGE, Mass. , Sept. 20, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first Thu, 20 Sep 2018 07:00:00 -0400 Merrimack Pharmaceuticals News Releases 11806 Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC) http://investors.merrimack.com/news-releases/news-release-details/merrimack-completes-enrollment-randomized-phase-2-sherloc-study CAMBRIDGE, Mass. , Sept. 6, 2018 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc.  (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead Thu, 06 Sep 2018 06:50:00 -0400 Merrimack Pharmaceuticals News Releases 11801 Merrimack Reports Second Quarter 2018 Financial Results http://investors.merrimack.com/news-releases/news-release-details/merrimack-reports-second-quarter-2018-financial-results - $18 million milestone payment received from Shire; Company continues to strengthen cash position from non-dilutive sources - - Two clinical readouts anticipated in 2018: randomized Phase 2 SHERLOC study of MM-121 in metastatic non-small cell lung cancer and Phase 1 study of MM-310 in solid tumors Tue, 07 Aug 2018 06:30:00 -0400 Merrimack Pharmaceuticals News Releases 11771